Hans Wandall

Company: GO Therapeutics

Job title: Chief Scientific Officer

Seminars:

C-Suite Fireside Chat – Strategizing the Search for the Next ADC Target to Dominate the Limelight – Where is the Next Best Target? 9:00 am

Scoping the current state of the ADC landscape to understand the white space in target selection and the gaps to exploit Collaborating to outline the lessons learned from traditional ADC targets, including HER2, to hypothesize the qualities of a successful target Proposing the realistic expectations for ADC target selection in 2025 and earmarking the predicted…Read more

day: Conference Day One

Clean Tumor Targets: The Necessary Starting Point for Next-Generation ADCs 10:15 am

Understanding how new ADC linkers and payloads promise incremental improvements in ADC profiles and how transformative improvement requires new targets Learning how targeting aberrantly glycosylated glycopeptide epitopes provides exquisitely clean solid tumor selectivity Exploring how Glycopeptide targeted ADCs promise to vastly reduce on-target off-tumor toxicity and open access to a broad range of cancer indicationsRead more

day: Conference Day One